findmyKOL

Benjamin Korman, MD

Basic profile

University of Rochester Medical Center

ORCIDNPI
RegionRochester, NY · NortheastSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding2018–2026Why? →

Benjamin Korman is a Rheumatology/Immunology physician affiliated with University of Rochester Medical Center. OpenAlex indexes 66 publications with 4,142 citations (h-index 24).

Overview

Scholarship

indexed output and impact (OpenAlex)
66publications

Distinct works indexed by OpenAlex, matched via ORCID.

4,142citations

Total citations across indexed works.

24h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
3NIH grants · 2018–2026

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

125 Lattimore Rd Ste G-110
Rochester, NY 146204159

Telephone

585-486-0901

Registry record last updated 29 Jun 2023.

View the NPPES registry record

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    26.5%
    Proton pump inhibitor18.2%
    Pantoprazole Sodium31%Esomeprazole Magnesium30%Dexlansoprazole Dr21%Omeprazole18%
    Part D<11 patients
    Corticosteroid8.3%
    Prednisone100%
    Part D16 patients
  • Cancer & immunology

    20.8%
    Folate Analog Metabolic Inhibitor10.7%
    Methotrexate100%
    Part D19 patients
    Interleukin-6 Receptor Antagonist8%
    Actemra Actpen100%
    Part D<11 patients

    + 1 more class in this area

  • Nervous system

    16.4%
    Gabapentinoids6.8%
    Gabapentin100%
    Part D<11 patients
    Cholinergic Receptor Agonist5.5%
    Pilocarpine Hcl59%Cevimeline Hcl41%
    Part D<11 patients

    + 2 more classes in this area

Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

3 NIH research awards on record, funded 20182026 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”